Targeting dendritic cells in vivo for cancer therapy

Irina Caminschi, Eugene Maraskovsky, William Ross Heath

Research output: Contribution to journalReview ArticleResearchpeer-review

51 Citations (Scopus)

Abstract

Monoclonal antibodies that recognize cell surface molecules have been used deliver antigenic cargo to dendritic cells (DC) for induction of immune responses. The encouraging anti-tumor immunity elicited using this immunization strategy suggests its suitability for clinical trials. This review discusses the complex network of DC, the functional specialization of DC subsets, the immunological outcomes of targeting different DC subsets and their cell surface receptors, and the requirements for the induction of effective anti-tumor CD4 and CD8 T cell responses that can recognize tumor-specific antigens. Finally, we review preclinical experiments and the progress toward targeting human DC in vivo.

Original languageEnglish
Article numberArticle 13
JournalFrontiers in Immunology
Volume3
Issue numberFEB
DOIs
Publication statusPublished - 2012
Externally publishedYes

Keywords

  • Antigen delivery
  • Dendritic cell subsets
  • Dendritic cells
  • Targeting
  • Vaccine

Cite this

Caminschi, Irina ; Maraskovsky, Eugene ; Heath, William Ross. / Targeting dendritic cells in vivo for cancer therapy. In: Frontiers in Immunology. 2012 ; Vol. 3, No. FEB.
@article{be9ae2291d4a400690cfb8522cf66616,
title = "Targeting dendritic cells in vivo for cancer therapy",
abstract = "Monoclonal antibodies that recognize cell surface molecules have been used deliver antigenic cargo to dendritic cells (DC) for induction of immune responses. The encouraging anti-tumor immunity elicited using this immunization strategy suggests its suitability for clinical trials. This review discusses the complex network of DC, the functional specialization of DC subsets, the immunological outcomes of targeting different DC subsets and their cell surface receptors, and the requirements for the induction of effective anti-tumor CD4 and CD8 T cell responses that can recognize tumor-specific antigens. Finally, we review preclinical experiments and the progress toward targeting human DC in vivo.",
keywords = "Antigen delivery, Dendritic cell subsets, Dendritic cells, Targeting, Vaccine",
author = "Irina Caminschi and Eugene Maraskovsky and Heath, {William Ross}",
year = "2012",
doi = "10.3389/fimmu.2012.00013",
language = "English",
volume = "3",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media",
number = "FEB",

}

Targeting dendritic cells in vivo for cancer therapy. / Caminschi, Irina; Maraskovsky, Eugene; Heath, William Ross.

In: Frontiers in Immunology, Vol. 3, No. FEB, Article 13, 2012.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Targeting dendritic cells in vivo for cancer therapy

AU - Caminschi, Irina

AU - Maraskovsky, Eugene

AU - Heath, William Ross

PY - 2012

Y1 - 2012

N2 - Monoclonal antibodies that recognize cell surface molecules have been used deliver antigenic cargo to dendritic cells (DC) for induction of immune responses. The encouraging anti-tumor immunity elicited using this immunization strategy suggests its suitability for clinical trials. This review discusses the complex network of DC, the functional specialization of DC subsets, the immunological outcomes of targeting different DC subsets and their cell surface receptors, and the requirements for the induction of effective anti-tumor CD4 and CD8 T cell responses that can recognize tumor-specific antigens. Finally, we review preclinical experiments and the progress toward targeting human DC in vivo.

AB - Monoclonal antibodies that recognize cell surface molecules have been used deliver antigenic cargo to dendritic cells (DC) for induction of immune responses. The encouraging anti-tumor immunity elicited using this immunization strategy suggests its suitability for clinical trials. This review discusses the complex network of DC, the functional specialization of DC subsets, the immunological outcomes of targeting different DC subsets and their cell surface receptors, and the requirements for the induction of effective anti-tumor CD4 and CD8 T cell responses that can recognize tumor-specific antigens. Finally, we review preclinical experiments and the progress toward targeting human DC in vivo.

KW - Antigen delivery

KW - Dendritic cell subsets

KW - Dendritic cells

KW - Targeting

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84872005280&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2012.00013

DO - 10.3389/fimmu.2012.00013

M3 - Review Article

AN - SCOPUS:84872005280

VL - 3

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - FEB

M1 - Article 13

ER -